市場調查報告書

巨細胞病毒 (CMV) 感染疾病:市場分析·流行病學·市場預測 (∼2027年)

Cytomegalovirus (CMV) Infections - Market Insights, Epidemiology, and Market Forecast-2028

出版商 DelveInsight Business Research LLP 商品編碼 524368
出版日期 內容資訊 英文 275 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
巨細胞病毒 (CMV) 感染疾病:市場分析·流行病學·市場預測 (∼2027年) Cytomegalovirus (CMV) Infections - Market Insights, Epidemiology, and Market Forecast-2028
出版日期: 2019年09月01日內容資訊: 英文 275 Pages
簡介

本報告提供主要7個國家巨細胞病毒 (CMV) 感染疾病的市場調查,彙整疾病的背景及概要,主要7個國家 (美國·德國·法國·義大利·西班牙·英國·日本) 的患病人數變化與預測,目前治療方法,未滿足需求,主要藥物的簡介,國家·各藥物種類的市場規模變化與預測,市場影響因素分析等資料。

第1章 重要考察

第2章 市場概要

第3章 疾病概要:CMV感染疾病

  • 簡介
  • CMV感染疾病臨床症狀
  • 病因
  • 風險要素
  • 遺傳模式
  • 徵兆·症狀
  • 病理生理學
    • 遺傳基因型分析
  • 診斷
    • 鑑別診斷
    • 診斷標準
    • 建議

第4章 流行病學·患者人口

  • 主要調查結果
  • 預測參數·患者人口

第5章 主要7個國家的整體患病人數

第6章 CMV感染疾病的流行病學:各國

  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本
    • 患病人口
    • 患病人口:各種類
    • 患病人口:巨細胞變異

第7章 目前治療方法

  • 治療目標
  • 一般的治療方法
  • 治療流程
  • 治療指南

第8章 未滿足需求

第9章 已上市藥物

  • 已上市藥物比較
  • Everolimus:Novartis Pharmaceuticals
  • raparimusu:Nobelpharma Co., Ltd
    • 藥物概要
    • 作用機制
    • 法律規章上的里程碑
    • 安全性·有效性
    • 副作用
    • 產品簡介

第10章 新的藥物

  • 新的藥物比較
  • epidiorekkusu:GW Pharmaceuticals
  • TAK-935:武田藥品工業
    • 藥物概要
    • 其他的開發活動
    • 臨床開發
    • 臨床試驗資訊
    • 產品簡介

第11章 市場分析CMV感染疾病:主要7個國家

  • 主要調查結果
  • 市場規模

第12章 市場展望:各國

第13章 美國:市場展望

  • 市場規模
    • 整體市場
    • 治療藥物別

第14章 歐盟5國:市場展望

  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 日本
    • 市場規模
    • 整體市場
    • 治療藥物別

第15章 市場成長的促進因素

第16章 市場障礙

第17章 附錄

第18章 DelveInsight的能力

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0014

DelveInsight's 'Cytomegalovirus (CMV) Infections- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cytomegalovirus (CMV) Infections in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

CMV affects young children mainly, but it is estimated that by age 30 in the United States, half of all adults are, or have been, infected. The virus can pass from an infected, pregnant mother to her child through the shared blood supply (umbilical cord).

Among healthy individuals, CMV infection usually causes no symptoms; however, when CMV is transmitted congenitally (congenital CMV or cCMV) it can cause severe sequel. Despite the relatively high prevalence of cCMV infections and potentially serious effects, many women are unfamiliar with the risk of cCMV.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Cytomegalovirus (CMV) Infections - Disease Understanding and Treatment Algorithm

Cytomegalovirus (CMV) is a commonly acquired infection and a member of the Herpesviridae family. Cytomegalovirus infection (CMV) is a viral infection that rarely causes obvious illness. There are three main types of CMV infections: acquired, recurring, or congenital. When the infection develops for the first time it is called acquired CMV. Recurrent CMV infection is defined as a new CMV infection in a patient with previous evidence of CMV infection in whom the virus has not been detected for at least 4 weeks during active surveillance. If a pregnant woman has an active CMV infection, the virus can be passed to the unborn baby and when it affects a baby in the womb, it's known as congenital CMV.

The primary infection manifests as an asymptomatic or self-limited febrile illness in immuno-competent individuals, after which CMV establishes life-long latency in various cells which serve as reservoirs for reactivation and as carriers of infection to susceptible individuals. There are certain groups at high risk for serious complications from CMV infection which includes: Pregnant Women, Transplant Patients with compromised immune systems, Patients with HIV, and Very low birth weight and premature infants. Cytomegalovirus (CMV) Infections Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total seroprevalence of CMV in 7MM, Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in 7MM, Number of Infants born with Congenital CMV in 7MM, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in 7MM, Number of CMV Patients among Solid Organ Transplants (SOT) in 7MM, Number of Refractory CMV Patients after HSCT/SOT in 7MM and CMV Retinitis among HIV Patients in 7MM) scenario of Cytomegalovirus (CMV) Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total diagnosed cases of CMV were found out to be approximately 110,540 in the 7MM. The number of CMV cases in the 7MM is expected to increase during the study period of 2017-2028. In 7MM, Hematopoietic Stem Cell Transplants (allogeneic HSCT) patients is increasing throughout the study period (2017-2028). While, HIV patients is decreasing throughout the study period (2017-2018) due to the High Active Antiretroviral Therapy (HAART).

Cytomegalovirus (CMV) Infections Drug Chapters

This segment of the Cytomegalovirus (CMV) Infections report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. Currently, antiviral drugs are used for CMV infection following transplant procedures. The drugs include valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination, etc. Recently, Prevymis (Letermovir) received FDA approval for the prevention of Human Cytomegalovirus (HCMV) infection in transplant patients.

There are two major strategies for CMV disease prevention after liver transplantation that includes preemptive therapy and antiviral prophylaxis. Before ART was widely available, daily use of oral ganciclovir (no longer marketed in the United States) for primary prophylaxis significantly reduced the incidence of CMV disease in a randomized, placebo-controlled trial.

The first-line options for therapy of CMV disease, are almost always intravenous ganciclovir or oral valganciclovir. Foscavir (FOS) is considered second-line therapy but is the preferred drug for patients who are failing GCV therapy due to viral resistance, or those who cannot be treated with GCV due to dose-limiting neutropenia or leucopenia. Another second-line therapy for CMV disease, cidofovir (Vistide, Gilead), is-like foscarnet-an inhibitor of the CMV DNA polymerase.

CMV Infection market is flooded with Generic products as the top-selling drugs have gone off-patent. Most recent gone off the patent drug was Valcyte, which lost its patent in 2013 and 2015 in the US and Europe, respectively.

Cytomegalovirus (CMV) Infections Market Outlook

According to DelveInsight, the market of Cytomegalovirus (CMV) Infections in 7MM was found to be approximately USD 1195.10 million in 2017. Cytomegalovirus (CMV) Infections market size in the United States accounted for approx. 68.16% of the total market in 2017.

Among the EU5 countries, in 2017, France had the highest market size with approximately USD 84.00 million, while Italy had the lowest market size for CMV Infection with approximately USD 47.00 million.

The market size of prophylactic & therapeutic CMV Infection in seven major markets was approximately USD 771.00 million & 423.00 million in 2017.

Cytomegalovirus (CMV) Infections Drugs Uptake

The dynamics of Cytomegalovirus Infection market is anticipated to change during the forecasted period owing to the expected launch of emerging therapies. There are many pipeline therapies under development for the prevention of Congenital Cytomegalovirus and treatment of Cytomegalovirus infection following transplant (allogeneic hematopoietic stem cell transplantation/Solid-organ transplantation). The therapies which are under development for the prophylaxis or treatment of CMV Infection are Maribavir (Shire), ATA230 (Atara Biotherapeutics), Viralym-M (ViraCyte), V160 (Merck Sharp & Dohme Corp), Cytotect-70 (BioTest, (EU5 only)) and Triplex (Helocyte).

Cytomegalovirus (CMV) Infections Report Insights

  • Patient Population by Total diagnosed cases
  • Infants born with Congenital CMV
  • CMV Patients among Hematopoietic Stem Cell Transplants (HSCT)
  • CMV Patients among Solid Organ Transplants (SOT)
  • Refractory CMV Patients after HSCT/SOT
  • CMV Retinitis among HIV Patients
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cytomegalovirus (CMV) Infections Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Cytomegalovirus (CMV) Infections Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Cytomegalovirus (CMV) Infections market
  • Organize sales and marketing efforts by identifying the best opportunities for Cytomegalovirus (CMV) Infections market
  • To understand the future market competition in the Cytomegalovirus (CMV) Infections market.

Table of Contents

1. Key Insight

2. Cytomegalovirus (CMV) Infections: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Cytomegalovirus (CMV) Infections in 2017
  • 2.2. Total Market Share (%) Distribution of Cytomegalovirus (CMV) Infections in 2028

3. Disease Background and Overview: Cytomegalovirus Infections (CMV)

  • 3.1. Introduction
  • 3.2. Classification of Cytomegalovirus Infections (CMV)
  • 3.3. Causes of CMV infections
  • 3.4. Symptoms of CMV infections
  • 3.5. Risk factors of CMV infections
  • 3.6. Pathophysiology of CMV infections
  • 3.7. Diagnosis of CMV infections

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Forecast Methodology
  • 4.3. Forecasting Assumptions
  • 4.4. Total Sero-Prevalence of CMV in 7MM
  • 4.5. Total Diagnosed CMV Patients in 7MM

5. Country Wise-Epidemiology of CMV Infections

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United States
    • 5.1.3. Number of Infants born with Congenital CMV in the United States
    • 5.1.4. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the United States
    • 5.1.5. Number of CMV Patients among Solid Organ Transplants (SOT) in the United States
    • 5.1.6. Number of Refractory CMV Patients after HSCT/SOT in the United States
    • 5.1.7. CMV Retinitis among HIV Patients in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Germany
    • 5.3.2. Number of Infants born with Congenital CMV in Germany
    • 5.3.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany
    • 5.3.4. Number of CMV Patients among Solid Organ Transplants (SOT) in Germany
    • 5.3.5. Number of Refractory CMV Patients after HSCT/SOT in Germany
    • 5.3.6. CMV Retinitis among HIV Patients in Germany
  • 5.4. France
    • 5.4.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in France
    • 5.4.2. Number of Infants born with Congenital CMV in France
    • 5.4.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France
    • 5.4.4. Number of CMV Patients among Solid Organ Transplants (SOT) in France
    • 5.4.5. Number of Refractory CMV Patients after HSCT/SOT in France
    • 5.4.6. CMV Retinitis among HIV Patients in France
  • 5.5. Italy
    • 5.5.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Italy
    • 5.5.2. Number of Infants born with Congenital CMV in Italy
    • 5.5.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy
    • 5.5.4. Number of CMV Patients among Solid Organ Transplants (SOT) in Italy
    • 5.5.5. Number of Refractory CMV Patients after HSCT/SOT in Italy
    • 5.5.6. CMV Retinitis among HIV Patients in Italy
  • 5.6. Spain
    • 5.6.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Spain
    • 5.6.2. Number of Infants born with Congenital CMV in Spain
    • 5.6.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain
    • 5.6.4. Number of CMV Patients among Solid Organ Transplants (SOT) in Spain
    • 5.6.5. Number of Refractory CMV Patients after HSCT/SOT in Spain
    • 5.6.6. CMV Retinitis among HIV Patients in Spain
  • 5.7. United Kingdom
    • 5.7.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United Kingdom
    • 5.7.2. Number of Infants born with Congenital CMV in the United Kingdom
    • 5.7.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the United Kingdom
    • 5.7.4. Number of CMV Patients among Solid Organ Transplants (SOT) in the United Kingdom
    • 5.7.5. Number of Refractory CMV Patients after HSCT/SOT in the United Kingdom
    • 5.7.6. CMV Retinitis among HIV Patients in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Japan
    • 5.8.3. Number of Infants born with Congenital CMV in Japan
    • 5.8.4. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Japan
    • 5.8.5. Number of CMV Patients among Solid Organ Transplants (SOT) in Japan
    • 5.8.6. Number of Refractory CMV Patients after HSCT/SOT in Japan
    • 5.8.7. CMV Retinitis among HIV Patients in Japan

6. Treatment Algorithm

  • 6.1. Canadian society of transplantation consensus workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report, 2005
  • 6.2. The Third International Consensus Guidelines on the management of Cytomegalovirus in Solid Organ Transplantation
  • 6.3. The Prevention and Management of CMV Disease after Solid Organ Transplantation: British Transplantation Society (2015)
  • 6.4. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
  • 6.5. Treatment of Cytomegalovirus(CMV)infection post renal transplantation (The guidelines for CMV infection post renal transplantation in Japanese Society for Clinical Renal Transplantation)
  • 6.6. Congenital Cytomegalovirus A European Expert Consensus Statement on Diagnosis and Management

7. Unmet Needs

8. Marketed Products

  • 8.1. Valcyte: Roche
    • 8.1.1. Product Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Safety and Efficacy
    • 8.1.5. Advantages and Disadvantages
    • 8.1.6. Side effects
    • 8.1.7. Product Profile
  • 8.2. Foscavir: Clinigen Group plc
    • 8.2.1. Product Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Safety and Efficacy
    • 8.2.5. Advantages and Disadvantages
    • 8.2.6. Side effects
    • 8.2.7. Product Profile
  • 8.3. CytoGam: CSL Behring
    • 8.3.1. Product Description
    • 8.3.2. Mechanism of Action
    • 8.3.3. Regulatory Milestones
    • 8.3.4. Safety and Efficacy
    • 8.3.5. Advantages and Disadvantages
    • 8.3.6. Side effects
    • 8.3.7. Product Profile
  • 8.4. Valtrex: GlaxoSmithKline
    • 8.4.1. Product Description
    • 8.4.2. Mechanism of Action
    • 8.4.3. Regulatory Milestones
    • 8.4.4. Safety and Efficacy
    • 8.4.5. Advantages and Disadvantages
    • 8.4.6. Side effects
    • 8.4.7. Product Profile
  • 8.5. Vistide: Gilead Sciences
    • 8.5.1. Product Description
    • 8.5.2. Mechanism of Action
    • 8.5.3. Regulatory Milestones
    • 8.5.4. Safety and Efficacy
    • 8.5.5. Side effects
    • 8.5.6. Product Profile
  • 8.6. Prevymis: Merck & Co.
    • 8.6.1. Product Description
    • 8.6.2. Mechanism of Action
    • 8.6.3. Regulatory Milestones
    • 8.6.4. Safety and Efficacy
    • 8.6.5. Advantages and Disadvantages
    • 8.6.6. Side effects
    • 8.6.7. Product Profile
  • 8.7. Cytotect CP: Biotest Pharma GmbH
    • 8.7.1. Product Description
    • 8.7.2. Regulatory Milestones
    • 8.7.3. Other development activities
    • 8.7.4. Advantages and Disadvantages
    • 8.7.5. Product Profile

9. Emerging Drugs

  • 9.1. Key cross competition
  • 9.2. CMV-Gyn (Cytotect 70): Biotest AG
    • 9.2.1. Product Description
    • 9.2.2. Other Developmental Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Advantages and Disadvantages
    • 9.2.5. Product Profile
  • 9.3. Maribavir: Shire Pharmaceuticals
    • 9.3.1. Product Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Advantages and Disadvantages
    • 9.3.6. Product Profile
  • 9.4. ATA230: Atara Biotherapeutics
    • 9.4.1. Product Description
    • 9.4.2. Other Developmental Activities
    • 9.4.3. Clinical Development
    • 9.4.4. Safety and Efficacy
    • 9.4.5. Product Profile
  • 9.5. Triplex: Helocyte
    • 9.5.1. Product Description
    • 9.5.2. Other Developmental Activities
    • 9.5.3. Clinical Development
    • 9.5.4. Safety and Efficacy
    • 9.5.5. Product Profile
  • 9.6. CSJ148: Novartis (Development suspended)
    • 9.6.1. Product Description
    • 9.6.2. Other Developmental Activities
    • 9.6.3. Clinical Development
    • 9.6.4. Product Profile
  • 9.7. Viralym-M: AlloVir
    • 9.7.1. Product Description
    • 9.7.2. Other Developmental Activities
    • 9.7.3. Clinical Development
    • 9.7.4. Safety and Efficacy
    • 9.7.5. Product Profile
  • 9.8. V160: Merck
    • 9.8.1. Product Description
    • 9.8.2. Clinical Development
    • 9.8.3. Safety and Efficacy
    • 9.8.4. Product Profile
  • 9.9. VBI-1501: VBI Vaccines
    • 9.9.1. Product Description
    • 9.9.2. Other Developmental Activities
    • 9.9.3. Clinical Development
    • 9.9.4. Safety and Efficacy
    • 9.9.5. Product Profile
  • 9.10. HB-101 (VaxWave): Hookipa Biotech
    • 9.10.1. Product Description
    • 9.10.2. Other Developmental Activities
    • 9.10.3. Clinical Development
    • 9.10.4. Safety and Efficacy
    • 9.10.5. Product Profile
  • 9.11. AVX601: AlphaVax
    • 9.11.1. Product Description
    • 9.11.2. Other Developmental Activities
    • 9.11.3. Clinical Development
    • 9.11.4. Safety and Efficacy
    • 9.11.5. Product Profile
  • 9.12. CMV glycoprotein B MF59 (gB/MF59): Sanofi
    • 9.12.1. Product Description
    • 9.12.2. Other developmental Activities
    • 9.12.3. Clinical Development
    • 9.12.4. Safety and Efficacy
    • 9.12.5. Product Profile
  • 9.13. ALVAC-CMV (vCP260): Sanofi
    • 9.13.1. Product Description
    • 9.13.2. Clinical Development
    • 9.13.3. Product Profile

10. Failed Therapies

  • 10.1. ASP0113: Astellas Pharma Global Development, Inc.
    • 10.1.1. Product Description
    • 10.1.2. Other Developmental Activities
    • 10.1.3. Clinical Development
    • 10.1.4. Safety and Efficacy
    • 10.1.5. Product Profile
  • 10.2. Brincidofovir: Chimerix Inc.
    • 10.2.1. Product Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile

11. Cytomegalovirus Infection: 7 Major Market Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of Cytomegalovirus Infection in 7MM
  • 11.3. Market Size of Prophylactic Cytomegalovirus Infection in 7MM
  • 11.4. Market Size of Prophylactic Cytomegalovirus Infection by therapies in 7MM
  • 11.5. Market Size of Therapeutic Cytomegalovirus Infection in 7MM
  • 11.6. Market Size of Therapeutic Cytomegalovirus Infection by therapies in 7MM

12. The United States Market Outlook

  • 12.1. United States Market Size
    • 12.1.1. Total Market size of Cytomegalovirus Infection
    • 12.1.2. Market Size of Prophylaxis CMV by therapies in the United States
    • 12.1.3. Market Size of Therapeutic CMV by therapies in the United States

13. EU-5 Countries: Market Outlook

  • 13.1. Germany
    • 13.1.1. Total Market size of Cytomegalovirus Infection
    • 13.1.2. Market Size of Prophylaxis CMV by therapies in Germany
    • 13.1.3. Market Size of Therapeutic CMV by therapies in Germany
  • 13.2. France
    • 13.2.1. Total Market size of Cytomegalovirus Infection
    • 13.2.2. Market Size of Prophylaxis CMV by therapies in France
    • 13.2.3. Market Size of Therapeutic CMV by therapies in France
  • 13.3. Italy
    • 13.3.1. Total Market size of Cytomegalovirus Infection
    • 13.3.2. Market Size of Prophylaxis CMV by therapies in Italy
    • 13.3.3. Market Size of Therapeutic CMV by therapies in Italy
  • 13.4. Spain
    • 13.4.1. Total Market size of Cytomegalovirus Infection
    • 13.4.2. Market Size of Prophylaxis CMV by therapies in Spain
    • 13.4.3. Market Size of Therapeutic CMV by therapies in Spain
  • 13.5. United Kingdom
    • 13.5.1. Total Market size of Cytomegalovirus Infection
    • 13.5.2. Market Size of Prophylaxis CMV by therapies in the United Kingdom
    • 13.5.3. Market Size of Therapeutic CMV by therapies in the United Kingdom
  • 13.6. Japan Market Outlook
    • 13.6.1. Total Market size of Cytomegalovirus Infection
    • 13.6.2. Market Size of Prophylaxis CMV by therapies in Japan
    • 13.6.3. Market Size of Therapeutic CMV by therapies in Japan

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1 List of diseases associated with HCMV (Human Cytomegalovirus)
  • Table 2 Total Sero-Prevalence of Cytomegalovirus Infection in 7MM (2017-2028)
  • Table 3 Total Diagnosed CMV Patients in 7MM (2017-2028)
  • Table 4 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United States (2017-2028)
  • Table 5 Number of Infants born with Congenital CMV in the United States (2017-2028)
  • Table 6 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2017-2028)
  • Table 7 Number of CMV Patients among SOT in the United States (2017-2028)
  • Table 8 Number of Refractory CMV Patients after HSCT/SOT in the United States (2017-2028)
  • Table 9 CMV Retinitis among HIV Patients in the United States (2017-2028)
  • Table 10 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Germany (2017-2028)
  • Table 11 Number of Infants born with Congenital CMV in Germany (2017-2028)
  • Table 12 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT)in Germany (2017-2028)
  • Table 13 Number of CMV Patients among SOT in Germany (2017-2028)
  • Table 14 Number of Refractory CMV Patients after HSCT/SOT in Germany (2017-2028)
  • Table 15 CMV Retinitis among HIV Patients in Germany (2017-2028)
  • Table 16 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in France (2017-2028)
  • Table 17 Number of Infants born with Congenital CMV in France (2017-2028)
  • Table 18 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2017-2028)
  • Table 19 Number of CMV Patients among SOT in France (2017-2028)
  • Table 20 Number of Refractory CMV Patients after HSCT/SOT in France (2017-2028)
  • Table 21 CMV Retinitis among HIV Patients in France (2017-2028)
  • Table 22 Total Diagnosed CMV Patients in Italy (2017-2028)
  • Table 23 Number of Infants born with Congenital CMV in Italy (2017-2028)
  • Table 24 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2017-2028)
  • Table 25 Number of CMV Patients among SOT in Italy (2017-2028)
  • Table 26 Number of Refractory CMV Patients after HSCT/SOT in Italy (2017-2028) (2017-2028)
  • Table 27 CMV Retinitis among HIV Patients in Italy (2017-2028)
  • Table 28 Total Diagnosed CMV Patients in Spain (2017-2028)
  • Table 29 Number of Infants born with Congenital CMV in Spain 2017-2028)
  • Table 30 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2017-2028)
  • Table 31 Number of CMV Patients among SOT in Spain (2017-2028)
  • Table 32 Number of Refractory CMV Patients after HSCT/SOT in Spain (2017-2028)
  • Table 33 CMV Retinitis among HIV Patients in Spain (2017-2028)
  • Table 34 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United Kingdom (2017-2028)
  • Table 35 Number of Infants born with Congenital CMV in the UK (2017-2028)
  • Table 36 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2017-2028)
  • Table 37 Number of CMV Patients among SOT in the United Kingdom (2017-2028)
  • Table 38 Number of Refractory CMV Patients after HSCT/SOT in the UK (2017-2028)
  • Table 39 CMV Retinitis among HIV Patients in the UK (2017-2028)
  • Table 40 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Japan (2017-2028)
  • Table 41 Number of Infants born with Congenital CMV in Japan (2017-2028)
  • Table 42 CMV Patients among HSCT Patients in Japan (2017-2028)
  • Table 43 Number of CMV Patients among SOT in Japan (2017-2028)
  • Table 44 Number of Refractory CMV Patients after HSCT/SOT in Japan (2017-2028)
  • Table 45 CMV Retinitis among HIV Patients in Japan (2017-2028)
  • Table 46 Recommendations for the treatment of CMV disease
  • Table 47 Antiviral drugs for CMV prevention and treatment in solid organ transplant recipients
  • Table 48 Treatment-related Recommendations
  • Table 49 Summary of Treatment Recommendations
  • Table 50 Phase II/III drug analysis
  • Table 51 Phase I/II drug analysis
  • Table 52 Cytotect CP70, Clinical Trial Description, 2019
  • Table 53 Maribavir, Clinical Trial Description, 2019
  • Table 54 CMV-pp65 CTLs, Clinical Trial Description, 2019
  • Table 55 Triplex, Clinical Trial Description, 2019
  • Table 56 CSJ148, Clinical Trial Description, 2019
  • Table 57 Viralym-M, Clinical Trial Description, 2019
  • Table 58 V160, Clinical Trial Description, 2019
  • Table 59 VBI-1501, Clinical Trial Description, 2019
  • Table 60 HB-101 Clinical Trial Description, 2019
  • Table 61 AVX601, Clinical Trial Description, 2019
  • Table 62 CMV glycoprotein B MF59: Clinical Trial Description, 2019
  • Table 63 ALVAC-CMV (vCP260): Clinical Trial Description, 2019
  • Table 64 ASP0113, Clinical Trial Description, 2019
  • Table 65 7 Major Market Size of Cytomegalovirus Infection in USD Million (2017-2028)
  • Table 66 7 Major Market Size of Prophylactic CMV Infection in USD Million (2017-2028)
  • Table 67 7 Major Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 68 7 Major Market Size of Therapeutic CMV Infection in USD Million (2017-2028)
  • Table 69 7 Major Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Table 70 Market Size of Cytomegalovirus Infection in the United States, in USD Million (2017-2028)
  • Table 71 United States Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 72 United States Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Table 73 Market Size of Cytomegalovirus Infection in Germany, in USD Million (2017-2028)
  • Table 74 Germany Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 75 Germany Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Table 76 Market Size of Cytomegalovirus Infection in France, in USD Million (2017-2028)
  • Table 77 France Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 78 France Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Table 79 Market Size of Cytomegalovirus Infection in Italy, in USD Million (2017-2028)
  • Table 80 Italy Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 81 Italy Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Table 82 Market Size of Cytomegalovirus Infection in Spain, in USD Million (2017-2028)
  • Table 83 Spain Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 84 Spain Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Table 85 Market Size of Cytomegalovirus Infection in the UK, in USD Million (2017-2028)
  • Table 86 United Kingdom Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 87 United Kingdom Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Table 88 Market Size of Cytomegalovirus Infection in Japan, in USD Million (2017-2028)
  • Table 89 Japan Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Table 90 Japan Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)

List of Figures

  • Figure 1 Classification of CMV
  • Figure 2 Risk Factors CMV infection
  • Figure 3 Mechanisms used by Human cytomegalovirus to interfere with cell-mediated immunity
  • Figure 4 Impact of the immune system on CMV
  • Figure 5 CMV Disease Mechanisms
  • Figure 6 Total Sero Prevalence of Cytomegalovirus Infection in 7MM (2017-2028)
  • Figure 7 Total Diagnosed CMV Patients in 7MM (2017-2028)
  • Figure 8 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United States (2017-2028)
  • Figure 9 Number of Infants born with Congenital CMV in the United States (2017-2028)
  • Figure 10 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2017-2028)
  • Figure 11 Number of CMV Patients among SOT in the United States (2017-2028)
  • Figure 12 Number of Refractory CMV Patients after HSCT/SOT in the United States (2017-2028)
  • Figure 13 CMV Retinitis among HIV Patients in the United States (2017-2028)
  • Figure 14 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Germany (2017-2028)
  • Figure 15 Number of Infants born with Congenital CMV in Germany (2017-2028)
  • Figure 16 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany (2017-2028)
  • Figure 17 Number of CMV Patients among SOT in Germany (2017-2028)
  • Figure 18 Number of Refractory CMV Patients after HSCT/SOT in Germany (2017-2028)
  • Figure 19 CMV Retinitis among HIV Patients in Germany (2017-2028)
  • Figure 20 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in France (2017-2028)
  • Figure 21 Number of Infants born with Congenital CMV in France (2017-2028)
  • Figure 22 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2017-2028)
  • Figure 23 Number of CMV Patients among SOT in France (2017-2028)
  • Figure 24 Number of Refractory CMV Patients after HSCT/SOT in France (2017-2028)
  • Figure 25 CMV Retinitis among HIV Patients in France (2017-2028)
  • Figure 26 Total Diagnosed CMV Patients in Italy (2017-2028)
  • Figure 27 Number of Infants born with Congenital CMV in Italy (2017-2028)
  • Figure 28 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2017-2028)
  • Figure 29 Number of CMV Patients among SOT in Italy (2017-2028)
  • Figure 30 Number of Refractory CMV Patients after HSCT/SOT in Italy (2017-2028)
  • Figure 31 CMV Retinitis among HIV Patients in Italy (2017-2028)
  • Figure 32 Total Diagnosed CMV Patients in Spain (2017-2028)
  • Figure 33 Number of Infants born with Congenital CMV in Spain (2017-2028)
  • Figure 34 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2017-2028)
  • Figure 35 Number of CMV Patients among SOT in Spain (2017-2028)
  • Figure 36 Number of Refractory CMV Patients after HSCT/SOT in Spain (2017-2028)
  • Figure 37 HIV Patients at High Risk of CMV in Spain (2017-2028)
  • Figure 38 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United Kingdom (2017-2028)
  • Figure 39 Number of Infants born with Congenital CMV in the UK (2017-2028)
  • Figure 40 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2017-2028)
  • Figure 41 Number of CMV Patients among SOT in the UK (2017-2028)
  • Figure 42 Number of Refractory CMV Patients after HSCT/SOT in the United Kingdom (2017-2028)
  • Figure 43 CMV Retinitis among HIV Patients in the UK (2017-2028)
  • Figure 44 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Japan (2017-2028)
  • Figure 45 Number of Infants born with Congenital CMV in Japan (2017-2028)
  • Figure 46 CMV Patients among HSCT in Japan (2017-2028)
  • Figure 47 Number of CMV Patients among SOT in Japan (2017-2028)
  • Figure 48 Number of Refractory CMV Patients after HSCT/SOT in Japan (2017-2028)
  • Figure 49 CMV Retinitis among HIV Patients in Japan (2017-2028)
  • Figure 50 Treatment of CMV Infections
  • Figure 51 Algorithm for treatment of Ganciclovir Resistance
  • Figure 52 Management of Congenital CMV infection
  • Figure 53 Proposed algorithm for the management of suspected antiviral drug resistance
  • Figure 54 Unmet Needs of CMV Infections
  • Figure 55 List of Marketed Drugs
  • Figure 56 List of Marketed Drugs Continued…..
  • Figure 57 7 Major Market Size of Cytomegalovirus Infection in USD Million (2017-2028)
  • Figure 58 7 Major Market Size of Prophylactic CMV Infection in USD Million (2017-2028)
  • Figure 59 7 Major Market Size of Prophylactic CMV Infection by therapies in USD Million (2017-2028)
  • Figure 60 7 Major Market Size of Therapeutic CMV Infection in USD Million (2017-2028)
  • Figure 61 7 Major Market Size of Therapeutic CMV Infection by therapies in USD Million (2017-2028)
  • Figure 62 Market Size of Cytomegalovirus Infection in the United States, USD Millions (2017-2028)
  • Figure 63 Market size of Prophylaxis CMV by therapies in the US, in USD Million (2017-2028)
  • Figure 64 Market size of Therapeutic CMV by therapies in the US, in USD Million (2017-2028)
  • Figure 65 Market Size of Cytomegalovirus Infection in Germany, USD Millions (2017-2028)
  • Figure 66 Market size of Prophylaxis CMV by therapies in Germany, in USD Million (2017-2028)
  • Figure 67 Market size of Therapeutic CMV by therapies in Germany, in USD Million (2017-2028)
  • Figure 68 Market Size of Cytomegalovirus Infection in France, USD Millions (2017-2028)
  • Figure 69 Market size of Prophylaxis CMV by therapies in France, in USD Million (2017-2028)
  • Figure 70 Market size of Therapeutic CMV by therapies in France, in USD Million (2017-2028)
  • Figure 71 Market Size of Cytomegalovirus Infection in Italy, USD Millions (2017-2028)
  • Figure 72 Market size of Prophylaxis CMV by therapies in Italy in USD Million (2017-2028)
  • Figure 73 Market size of Therapeutic CMV by therapies in Italy in USD Million (2017-2028)
  • Figure 74 Market Size of Cytomegalovirus Infection in Spain, USD Millions (2017-2028)
  • Figure 75 Market size of Prophylaxis CMV by therapies in Spain, in USD Million (2017-2028)
  • Figure 76 Market size of Therapeutic CMV by therapies in Spain, in USD Million (2017-2028)
  • Figure 77 Market Size of Cytomegalovirus Infection in the UK, USD Millions (2017-2028)
  • Figure 78 Market size of Prophylaxis CMV by therapies in the UK, in USD Million (2017-2028)
  • Figure 79 Market size of Therapeutic CMV by therapies in the UK, in USD Million (2017-2028)
  • Figure 80 Market Size of Cytomegalovirus Infection in Japan, USD Millions (2017-2028)
  • Figure 81 Market size of Prophylaxis CMV by therapies in Japan, in USD Million (2017-2028)
  • Figure 82 Market size of Therapeutic CMV by therapies in Japan, in USD Million (2017-2028)
  • Figure 83 Market Drivers
  • Figure 84 Market Barriers
Back to Top